Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial

BACKGROUND AND OBJECTIVES: Endoxifen is the active metabolite of tamoxifen, and a minimal plasma concentration of 16 nM has been suggested as a threshold above which it is effective in reducing the risk of breast cancer recurrence. The aim of the current analysis was to investigate the cost-effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Braal, C. Louwrens, Kleijburg, Anne, Jager, Agnes, Koolen, Stijn L. W., Mathijssen, Ron H. J., Corro Ramos, Isaac, Wetzelaer, Pim, Uyl-de Groot, Carin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844136/
https://www.ncbi.nlm.nih.gov/pubmed/35020170
http://dx.doi.org/10.1007/s40261-021-01114-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844136/
https://www.ncbi.nlm.nih.gov/pubmed/35020170
http://dx.doi.org/10.1007/s40261-021-01114-6

Ejemplares similares